Congress Wealth Management LLC DE Has $10.99 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Congress Wealth Management LLC DE lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 23.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 229,765 shares of the biopharmaceutical company’s stock after selling 68,660 shares during the period. Congress Wealth Management LLC DE owned 0.18% of Halozyme Therapeutics worth $10,985,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $29,000. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics during the 4th quarter worth $29,000. Smartleaf Asset Management LLC lifted its holdings in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust increased its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 322 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Benchmark reiterated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.78.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock worth $1,754,451 in the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 1.7 %

HALO opened at $64.02 on Tuesday. The company has a fifty day moving average price of $58.39 and a two-hundred day moving average price of $54.68. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The company has a market cap of $7.91 billion, a P/E ratio of 18.66, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.